Pub Date : 2026-03-01Epub Date: 2025-06-28DOI: 10.4103/mgr.MEDGASRES-D-24-00136
Jun Lu, Wentao Ji, Yu Guo, Shun Yang, Didi Yang, Bo Li, Lulong Bo
JOURNAL/mgres/04.03/01612956-202603000-00003/figure1/v/2025-06-28T140100Z/r/image-tiff Hypoxemia during propofol sedation for gastrointestinal endoscopic procedures is a significant risk and is often exacerbated by inadequate preoxygenation. Effective preoxygenation strategies are essential for reducing the incidence of hypoxemia, especially in high-risk patients. This study aimed to evaluate the efficacy of an enhanced preoxygenation protocol for mitigating hypoxemia during propofol sedation during gastroscopy. In a prospective, randomized, controlled design, patients undergoing gastroscopy were assigned to either an intervention group (enhanced preoxygenation) or a nonintervention group (standard care). The intervention protocol involved the administration of eight tidal volume breaths over 1 minute at an oxygen flow rate of 10 L/min via a tight-fitting face mask, with clinical supervision by an endoscopy nurse. The primary outcome was the incidence of hypoxemia, defined as a peripheral oxygen saturation level of less than 90% at any point during the gastroscopy procedure. Compared with the nonintervention group, the intervention group had a significantly lower incidence of hypoxemia. This effect was particularly pronounced in high-risk patients, including elderly individuals and those with elevated body mass indices. No significant adverse events were observed during the procedure. These results suggest that enhanced preoxygenation may effectively alleviate the occurrence of hypoxemia during propofol sedation in gastrointestinal endoscopic procedures. Further research is needed to assess the broader applicability of this approach and explore additional strategies for optimizing preoxygenation in endoscopic procedures.
{"title":"Efficacy of enhanced preoxygenation protocols in mitigating hypoxemia during propofol sedation for gastrointestinal endoscopic procedures: a prospective, randomized, controlled study.","authors":"Jun Lu, Wentao Ji, Yu Guo, Shun Yang, Didi Yang, Bo Li, Lulong Bo","doi":"10.4103/mgr.MEDGASRES-D-24-00136","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00136","url":null,"abstract":"<p><p>JOURNAL/mgres/04.03/01612956-202603000-00003/figure1/v/2025-06-28T140100Z/r/image-tiff Hypoxemia during propofol sedation for gastrointestinal endoscopic procedures is a significant risk and is often exacerbated by inadequate preoxygenation. Effective preoxygenation strategies are essential for reducing the incidence of hypoxemia, especially in high-risk patients. This study aimed to evaluate the efficacy of an enhanced preoxygenation protocol for mitigating hypoxemia during propofol sedation during gastroscopy. In a prospective, randomized, controlled design, patients undergoing gastroscopy were assigned to either an intervention group (enhanced preoxygenation) or a nonintervention group (standard care). The intervention protocol involved the administration of eight tidal volume breaths over 1 minute at an oxygen flow rate of 10 L/min via a tight-fitting face mask, with clinical supervision by an endoscopy nurse. The primary outcome was the incidence of hypoxemia, defined as a peripheral oxygen saturation level of less than 90% at any point during the gastroscopy procedure. Compared with the nonintervention group, the intervention group had a significantly lower incidence of hypoxemia. This effect was particularly pronounced in high-risk patients, including elderly individuals and those with elevated body mass indices. No significant adverse events were observed during the procedure. These results suggest that enhanced preoxygenation may effectively alleviate the occurrence of hypoxemia during propofol sedation in gastrointestinal endoscopic procedures. Further research is needed to assess the broader applicability of this approach and explore additional strategies for optimizing preoxygenation in endoscopic procedures.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"16 1","pages":"12-18"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-06-28DOI: 10.4103/mgr.MEDGASRES-D-24-00111
Songyang Peng, Lin Zeng, Bing Lu, Qizheng Li
Spinal cord injury (SCI) is a severe trauma that leads to significant motor, sensory, and autonomic dysfunction, imposing a substantial disease burden and economic costs globally. The pathophysiology of SCI involves primary and secondary injury stages, with the latter characterized by inflammatory responses, apoptosis, and tissue necrosis. Current therapeutic interventions, including pharmacological treatments and stem cell therapies, provide limited benefits and do not fully address the therapeutic effects on SCI. Hyperbaric oxygen therapy (HBOT), which delivers 100% oxygen at pressures exceeding 1 atmosphere absolute, has shown potential in SCI animal models due to its antiapoptotic, antioxidant, anti-inflammatory, and angiogenesis-promoting effects, thereby limiting secondary injury. Clinical studies have also demonstrated some efficacy of HBOT in treating SCI; however, the optimal timing, duration, and treatment cycles of HBOT remain contentious, and long-term efficacy has yet to be assessed. This review synthesizes the basic research and clinical practice of HBOT for SCI, thereby summarizing the main mechanistic pathways and demonstrating its clinical effects. Future large-scale, multicenter clinical studies are warranted to determine the efficacy and safety of HBOT in treating SCI and explore combined therapeutic modalities for a more comprehensive treatment approach.
{"title":"Application of hyperbaric oxygen therapy in the treatment of spinal cord injury: insights from preclinical to clinical evidence.","authors":"Songyang Peng, Lin Zeng, Bing Lu, Qizheng Li","doi":"10.4103/mgr.MEDGASRES-D-24-00111","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00111","url":null,"abstract":"<p><p>Spinal cord injury (SCI) is a severe trauma that leads to significant motor, sensory, and autonomic dysfunction, imposing a substantial disease burden and economic costs globally. The pathophysiology of SCI involves primary and secondary injury stages, with the latter characterized by inflammatory responses, apoptosis, and tissue necrosis. Current therapeutic interventions, including pharmacological treatments and stem cell therapies, provide limited benefits and do not fully address the therapeutic effects on SCI. Hyperbaric oxygen therapy (HBOT), which delivers 100% oxygen at pressures exceeding 1 atmosphere absolute, has shown potential in SCI animal models due to its antiapoptotic, antioxidant, anti-inflammatory, and angiogenesis-promoting effects, thereby limiting secondary injury. Clinical studies have also demonstrated some efficacy of HBOT in treating SCI; however, the optimal timing, duration, and treatment cycles of HBOT remain contentious, and long-term efficacy has yet to be assessed. This review synthesizes the basic research and clinical practice of HBOT for SCI, thereby summarizing the main mechanistic pathways and demonstrating its clinical effects. Future large-scale, multicenter clinical studies are warranted to determine the efficacy and safety of HBOT in treating SCI and explore combined therapeutic modalities for a more comprehensive treatment approach.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"16 1","pages":"33-40"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318580/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-06-28DOI: 10.4103/mgr.MEDGASRES-D-25-00083
Youmna Abdelghany, Nirav G Shah, Andrea Levine, Jason J Rose
{"title":"Combined carbon monoxide poisoning and smoke inhalational injury in a case of severe underlying lung disease.","authors":"Youmna Abdelghany, Nirav G Shah, Andrea Levine, Jason J Rose","doi":"10.4103/mgr.MEDGASRES-D-25-00083","DOIUrl":"10.4103/mgr.MEDGASRES-D-25-00083","url":null,"abstract":"","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"16 1","pages":"90-91"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-06-28DOI: 10.4103/mgr.MEDGASRES-D-25-00109
Lu Yang, Ding Nan, Xuehua Liu, Jing Zhang, Yi Zhang, Fang Liang, Wanqiu Zhu, Jing Yang
JOURNAL/mgres/04.03/01612956-202603000-00002/figure1/v/2025-06-28T140100Z/r/image-tiff Paroxysmal sympathetic hyperactivity syndrome (PSH) is common in patients with severe craniocerebral injuries. Carbon monoxide poisoning (ACOP) may lead to secondary PSH, and hyperbaric oxygen (HBO) is an important treatment method for ACOP that can promote the dissociation of carboxyhemoglobin and reduce the long-term sequelae of ACOP. To explore the risk factors and clinical characteristics of PSH secondary to acute ACOP and to investigate the efficacy of HBO treatment, a retrospective analysis was performed on patients with moderate to severe ACOP admitted to the Hyperbaric Oxygen Department of Beijing Chaoyang Hospital, Capital Medical University, from January 1, 2018 to December 31, 2024. Three patients developed PSH during hospitalization and were classified into the PSH group, while the remaining 50 patients were in the non-PSH group. Univariate Fisher's exact test indicated that a coma duration of more than 72 hours was related to the occurrence of PSH after ACOP, and irregular HBO treatment after onset might be associated with the occurrence of PSH after ACOP. All three PSH patients developed paroxysmal postural or dystonic disorders after onset, accompanied by sympathetic excitation manifestations such as increased heart rate, respiratory rate, elevated blood pressure, and fever. Antiepileptic drugs had poor effects, and the attacks were effectively controlled after HBO treatment combined with adjusted drug therapy. The results indicate that for patients with severe carbon monoxide poisoning, especially those with a long coma duration or irregular HBO treatment after onset, if epileptic seizures occur during the disease course and are accompanied by sympathetic excitation manifestations, the possibility of PSH should be considered. Regular HBO treatment is of great significance for controlling the onset of symptoms.
{"title":"Hyperbaric oxygen for paroxysmal sympathetic hyperactivity syndrome after acute carbon monoxide poisoning.","authors":"Lu Yang, Ding Nan, Xuehua Liu, Jing Zhang, Yi Zhang, Fang Liang, Wanqiu Zhu, Jing Yang","doi":"10.4103/mgr.MEDGASRES-D-25-00109","DOIUrl":"10.4103/mgr.MEDGASRES-D-25-00109","url":null,"abstract":"<p><p>JOURNAL/mgres/04.03/01612956-202603000-00002/figure1/v/2025-06-28T140100Z/r/image-tiff Paroxysmal sympathetic hyperactivity syndrome (PSH) is common in patients with severe craniocerebral injuries. Carbon monoxide poisoning (ACOP) may lead to secondary PSH, and hyperbaric oxygen (HBO) is an important treatment method for ACOP that can promote the dissociation of carboxyhemoglobin and reduce the long-term sequelae of ACOP. To explore the risk factors and clinical characteristics of PSH secondary to acute ACOP and to investigate the efficacy of HBO treatment, a retrospective analysis was performed on patients with moderate to severe ACOP admitted to the Hyperbaric Oxygen Department of Beijing Chaoyang Hospital, Capital Medical University, from January 1, 2018 to December 31, 2024. Three patients developed PSH during hospitalization and were classified into the PSH group, while the remaining 50 patients were in the non-PSH group. Univariate Fisher's exact test indicated that a coma duration of more than 72 hours was related to the occurrence of PSH after ACOP, and irregular HBO treatment after onset might be associated with the occurrence of PSH after ACOP. All three PSH patients developed paroxysmal postural or dystonic disorders after onset, accompanied by sympathetic excitation manifestations such as increased heart rate, respiratory rate, elevated blood pressure, and fever. Antiepileptic drugs had poor effects, and the attacks were effectively controlled after HBO treatment combined with adjusted drug therapy. The results indicate that for patients with severe carbon monoxide poisoning, especially those with a long coma duration or irregular HBO treatment after onset, if epileptic seizures occur during the disease course and are accompanied by sympathetic excitation manifestations, the possibility of PSH should be considered. Regular HBO treatment is of great significance for controlling the onset of symptoms.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"16 1","pages":"6-11"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JOURNAL/mgres/04.03/01612956-202603000-00005/figure1/v/2025-06-28T140100Z/r/image-tiff Exercise-induced fatigue limits athletic performance. Molecular hydrogen is an effective treatment for relieving fatigue, but the exact mechanism is not clear. In our study, a mouse model of fatigue was established to explore the molecular mechanism by which hydrogen-rich water reduces exercise-induced fatigue. The results showed that hydrogen-rich water improved the motor function of fatigue mice, reduced the levels of fatigue-related biomarkers (blood urea nitrogen, lactate, and creatine kinase), and alleviated gastrocnemius muscle injury. Furthermore, ultrahigh-performance liquid chromatography-mass spectrometry revealed that hydrogen-rich water upregulated the expression of immune response gene 1 (IRG1), increased the abnormally reduced levels of itaconic acid due to fatigue, and subsequently activated the downstream nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway. Finally, C2C12 cells exposed to an IRG1 inhibitor (IRG1-IN) or 4-octyl itaconic acid (4-OI) were treated with hydrogen-rich water, indicating that hydrogen-rich water effectively upregulated the expression of Nrf2 and HO-1 in cells. In summary, hydrogen-rich water alleviates exercise-induced fatigue by activating the IRG1-itaconic acid/Nrf2/HO-1 pathway and inhibiting oxidative stress.
{"title":"Mechanism by which hydrogen-rich water mitigates exercise-induced fatigue: activation of the immunoresponsive gene 1-itaconate/nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway.","authors":"Yinyin Zhang, Yajing Ying, Xianpeng Zu, Lingling Ding, Xuan Shi, Jing Wang, Xiangtong Li, Chujian Li, Qicheng Zhou, Hui Shen, Hongxia Li, Hongtao Lu, Jin Cheng","doi":"10.4103/mgr.MEDGASRES-D-24-00148","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00148","url":null,"abstract":"<p><p>JOURNAL/mgres/04.03/01612956-202603000-00005/figure1/v/2025-06-28T140100Z/r/image-tiff Exercise-induced fatigue limits athletic performance. Molecular hydrogen is an effective treatment for relieving fatigue, but the exact mechanism is not clear. In our study, a mouse model of fatigue was established to explore the molecular mechanism by which hydrogen-rich water reduces exercise-induced fatigue. The results showed that hydrogen-rich water improved the motor function of fatigue mice, reduced the levels of fatigue-related biomarkers (blood urea nitrogen, lactate, and creatine kinase), and alleviated gastrocnemius muscle injury. Furthermore, ultrahigh-performance liquid chromatography-mass spectrometry revealed that hydrogen-rich water upregulated the expression of immune response gene 1 (IRG1), increased the abnormally reduced levels of itaconic acid due to fatigue, and subsequently activated the downstream nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway. Finally, C2C12 cells exposed to an IRG1 inhibitor (IRG1-IN) or 4-octyl itaconic acid (4-OI) were treated with hydrogen-rich water, indicating that hydrogen-rich water effectively upregulated the expression of Nrf2 and HO-1 in cells. In summary, hydrogen-rich water alleviates exercise-induced fatigue by activating the IRG1-itaconic acid/Nrf2/HO-1 pathway and inhibiting oxidative stress.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"16 1","pages":"26-32"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-06-28DOI: 10.4103/mgr.MEDGASRES-D-25-00040
Carolina Calderón-Chiu, Montserrat Calderón-Santoyo, Juan Arturo Ragazzo-Sánchez
{"title":"Feasibility of leaf protein hydrolysates to reduce reactive oxygen species and cancer cell proliferation.","authors":"Carolina Calderón-Chiu, Montserrat Calderón-Santoyo, Juan Arturo Ragazzo-Sánchez","doi":"10.4103/mgr.MEDGASRES-D-25-00040","DOIUrl":"10.4103/mgr.MEDGASRES-D-25-00040","url":null,"abstract":"","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"16 1","pages":"88-89"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-06-28DOI: 10.4103/mgr.MEDGASRES-D-25-00024
Matthew Chibunna Igwe, Esther Ugo Alum, Alphonsus Ogbonna Ogbuabor
Chronic obstructive pulmonary disease (COPD) is a major global health challenge, disproportionately affecting aging populations in low- and middle-income countries, including Sub-Saharan Africa (SSA). With an increasing prevalence driven by indoor air pollution, tobacco use, and occupational hazards, COPD remains underdiagnosed underdiagnosed and undertreated in the region due to inadequate healthcare infrastructure and resource constraints. This review highlights the critical role of medical gases, particularly long-term oxygen therapy (LTOT), in managing COPD, improving quality of life, and reducing mortality in patients with severe hypoxemia. Although LTOT is well-established in high-income countries, its implementation in SSA faces significant barriers, including limited access, cost, and insufficient awareness. This review analyzes COPD management, LTOT benefits, healthcare policies, and aging demographics in SSA, focusing on experimental studies and synthesizing data for coherence. Relevant articles in English published from 2014 to 2025 were retrieved from PubMed, Scopus, and WHO. Through a comprehensive analysis of the epidemiology of COPD in SSA, the challenges of integrating LTOT, and successful case studies from comparable regions, this review identifies key opportunities for addressing these gaps. Recommendations include strengthening healthcare infrastructure, fostering policy frameworks for LTOT integration, leveraging community engagement, and enhancing patient education. By addressing these challenges holistically and fostering regional and global collaborations, SSA can mitigate the growing burden of COPD and improve health outcomes for its aging populations.
{"title":"Medical gases and long-term oxygen therapy: reducing the chronic obstructive pulmonary disease burden in aging populations in Sub-Saharan Africa.","authors":"Matthew Chibunna Igwe, Esther Ugo Alum, Alphonsus Ogbonna Ogbuabor","doi":"10.4103/mgr.MEDGASRES-D-25-00024","DOIUrl":"10.4103/mgr.MEDGASRES-D-25-00024","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) is a major global health challenge, disproportionately affecting aging populations in low- and middle-income countries, including Sub-Saharan Africa (SSA). With an increasing prevalence driven by indoor air pollution, tobacco use, and occupational hazards, COPD remains underdiagnosed underdiagnosed and undertreated in the region due to inadequate healthcare infrastructure and resource constraints. This review highlights the critical role of medical gases, particularly long-term oxygen therapy (LTOT), in managing COPD, improving quality of life, and reducing mortality in patients with severe hypoxemia. Although LTOT is well-established in high-income countries, its implementation in SSA faces significant barriers, including limited access, cost, and insufficient awareness. This review analyzes COPD management, LTOT benefits, healthcare policies, and aging demographics in SSA, focusing on experimental studies and synthesizing data for coherence. Relevant articles in English published from 2014 to 2025 were retrieved from PubMed, Scopus, and WHO. Through a comprehensive analysis of the epidemiology of COPD in SSA, the challenges of integrating LTOT, and successful case studies from comparable regions, this review identifies key opportunities for addressing these gaps. Recommendations include strengthening healthcare infrastructure, fostering policy frameworks for LTOT integration, leveraging community engagement, and enhancing patient education. By addressing these challenges holistically and fostering regional and global collaborations, SSA can mitigate the growing burden of COPD and improve health outcomes for its aging populations.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"16 1","pages":"46-52"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-04-19DOI: 10.4103/mgr.MEDGASRES-D-24-00155
Lei Zhang, Jiao Zhu, Zhengjie Miao, Haoli Mao, Hong Jiang
JOURNAL/mgres/04.03/01612956-202603000-00004/figure1/v/2025-06-28T140100Z/r/image-tiff Inhalation anesthetics may trigger the hypothalamic-pituitary-adrenal axis. FK-506 binding protein (FKBP5) is a critical regulator of the hypothalamic-pituitary-adrenal axis and has been implicated in postoperative cognitive dysfunction. However, how inhalation anesthetics affect the expression and function of FKBP5 in the brain is unclear. We employed single-nucleus RNA sequencing to delineate the hippocampal transcriptomic profiles of the brains of aged marmosets and mice after sevoflurane anesthesia. The results of single-nucleus RNA sequencing revealed that long-term exposure (6 hours) to sevoflurane significantly increased FKBP5 expression in the hippocampus of aged marmosets and mice, especially in microglia. Western blot assay also verified the above results. The Barnes maze test showed that, compared with heterozygous control mice, microglia-specific FKBP5 conditional knockout mice exhibited improved neurocognitive function after sevoflurane/surgery. Transcriptome sequencing analysis was performed on the brains of microglia-specific FKBP5 conditional knockout mice and heterozygous mice after sevoflurane/surgery and further revealed that FKBP5 was related mainly to inflammatory signaling pathways. Therefore, these findings indicate that long-term exposure to sevoflurane increases FKBP5 expression in the hippocampus of aged marmosets and mice, which thereby affects inflammatory signaling pathways and leads to postoperative cognitive dysfunction.
{"title":"Mechanisms by which sevoflurane affects cognitive function in aged marmosets and mice: up-regulation of FKBP5 expression in brain microglia.","authors":"Lei Zhang, Jiao Zhu, Zhengjie Miao, Haoli Mao, Hong Jiang","doi":"10.4103/mgr.MEDGASRES-D-24-00155","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00155","url":null,"abstract":"<p><p>JOURNAL/mgres/04.03/01612956-202603000-00004/figure1/v/2025-06-28T140100Z/r/image-tiff Inhalation anesthetics may trigger the hypothalamic-pituitary-adrenal axis. FK-506 binding protein (FKBP5) is a critical regulator of the hypothalamic-pituitary-adrenal axis and has been implicated in postoperative cognitive dysfunction. However, how inhalation anesthetics affect the expression and function of FKBP5 in the brain is unclear. We employed single-nucleus RNA sequencing to delineate the hippocampal transcriptomic profiles of the brains of aged marmosets and mice after sevoflurane anesthesia. The results of single-nucleus RNA sequencing revealed that long-term exposure (6 hours) to sevoflurane significantly increased FKBP5 expression in the hippocampus of aged marmosets and mice, especially in microglia. Western blot assay also verified the above results. The Barnes maze test showed that, compared with heterozygous control mice, microglia-specific FKBP5 conditional knockout mice exhibited improved neurocognitive function after sevoflurane/surgery. Transcriptome sequencing analysis was performed on the brains of microglia-specific FKBP5 conditional knockout mice and heterozygous mice after sevoflurane/surgery and further revealed that FKBP5 was related mainly to inflammatory signaling pathways. Therefore, these findings indicate that long-term exposure to sevoflurane increases FKBP5 expression in the hippocampus of aged marmosets and mice, which thereby affects inflammatory signaling pathways and leads to postoperative cognitive dysfunction.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":" ","pages":"19-25"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-06-28DOI: 10.4103/mgr.MEDGASRES-D-24-00162
Ming Sun, Hairui Liang, Yong Chen, Siyu Duan, Rongda Xu, Zhencun Cai
JOURNAL/mgres/04.03/01612956-202603000-00001/figure1/v/2025-06-28T140100Z/r/image-tiff Avascular necrosis of the femoral head is a condition resulting from disrupted blood supply, leading to ischemia and bone tissue necrosis. Core decompression (CD) restores the blood supply through pressure relief, whereas hyperbaric oxygen (HBO) enhances tissue oxygenation and promotes bone repair. Their combined use may complement each other in improving blood supply, promoting bone healing, and inhibiting disease progression, thus achieving a better therapeutic effect. To assess and compare the efficacy of HBO and/or CD for treating mild to moderate femoral head avascular necrosis, a retrospective study was conducted on patients diagnosed with Ficat stage II non-traumatic osteonecrosis between January 2017 and January 2022 at the Affiliated Central Hospital of Shenyang Medical University, China. A total of 72 patients were divided into HBO, CD, and combination groups, with 24 patients in each group. After 1 year of follow-up, 90% of patients in the HBO group, 85% in the CD group, and 95% in the combination group showed satisfactory improvements in hip joint function. The SF-36 quality of life questionnaire scale scores also significantly improved in all three groups, with the combination group showing the most significant improvement. These findings suggest that HBO offers promising potential for treating non-traumatic femoral head necrosis, with efficacy similar to that of CD. The combination group showed the most significant improvement in both hip joint function and quality of life.
{"title":"A retrospective comparison of hyperbaric oxygen and core decompression for mild to moderate avascular necrosis of the femoral head.","authors":"Ming Sun, Hairui Liang, Yong Chen, Siyu Duan, Rongda Xu, Zhencun Cai","doi":"10.4103/mgr.MEDGASRES-D-24-00162","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00162","url":null,"abstract":"<p><p>JOURNAL/mgres/04.03/01612956-202603000-00001/figure1/v/2025-06-28T140100Z/r/image-tiff Avascular necrosis of the femoral head is a condition resulting from disrupted blood supply, leading to ischemia and bone tissue necrosis. Core decompression (CD) restores the blood supply through pressure relief, whereas hyperbaric oxygen (HBO) enhances tissue oxygenation and promotes bone repair. Their combined use may complement each other in improving blood supply, promoting bone healing, and inhibiting disease progression, thus achieving a better therapeutic effect. To assess and compare the efficacy of HBO and/or CD for treating mild to moderate femoral head avascular necrosis, a retrospective study was conducted on patients diagnosed with Ficat stage II non-traumatic osteonecrosis between January 2017 and January 2022 at the Affiliated Central Hospital of Shenyang Medical University, China. A total of 72 patients were divided into HBO, CD, and combination groups, with 24 patients in each group. After 1 year of follow-up, 90% of patients in the HBO group, 85% in the CD group, and 95% in the combination group showed satisfactory improvements in hip joint function. The SF-36 quality of life questionnaire scale scores also significantly improved in all three groups, with the combination group showing the most significant improvement. These findings suggest that HBO offers promising potential for treating non-traumatic femoral head necrosis, with efficacy similar to that of CD. The combination group showed the most significant improvement in both hip joint function and quality of life.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"16 1","pages":"1-5"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-06-28DOI: 10.4103/mgr.MEDGASRES-D-24-00150
Xiao-Tong Ding, Jin-Zhao Huang, Qiu-Song Shen, Rui-Yu Wang, Hou-Ming Kan
Pulsed radiofrequency combined with ozone therapy has been a newly proposed treatment method for zoster-associated pain in recent years. To explore the effectiveness of a regimen of pulsed radiofrequency combined with ozone for the treatment of zoster-associated pain. We searched commonly used English databases (the Cochrane Library, PubMed, CINAHL, Embase, and Web of Science) and Chinese databases (the CNKI, WanFang, CBM, and VIP databases) for randomized controlled trials. Two researchers independently screened the literature on the basis of the set conditions and extracted data from the included literature. The meta-analysis was conducted via Review Manager 5.4 software. A meta-analysis was conducted on 18 studies, with a total of 1496 participants (742 in the experimental group and 754 in the control group). The results revealed that the pulsed radiofrequency combined with ozone presented lower unidimensional pain scores (standardized mean difference [SMD] = -1.55, 95% confidence interval [CI] = [-2.04, -1.06]; heterogeneity: P < 0.00001, I2 = 94%; test effect: Z = 6.18, P < 0.00001), a lower pain rating index (mean difference [MD] = -2.65, 95% CI = [-3.86, -1.44]; heterogeneity: P = 0.001, I2 = 85%; test effect: Z = 4.29, P < 0.0001) and presented pain intensity scores (MD = -0.58, 95% CI = [-0.62, -0.54]; heterogeneity: P = 0.61, I2 = 0%; test effect: Z = 27.91, P < 0.00001), a lower Pittsburgh sleep quality index (MD = -1.62, 95% CI = [-2.94, -0.31]; heterogeneity: P < 0.00001, I2 = 93%; test effect: Z = 2.42, P = 0.02), and lower interleukin-6 expression levels (SMD = -1.94, 95% CI = [-2.91, -0.97]; heterogeneity: P < 0.00001, I2 = 93%; test effect: Z = 3.92, P < 0.0001), lower gabapentin consumption (MD = -146.92, 95% CI = [-189.93, -103.91]; heterogeneity: P = 0.23, I2 = 30%; test effect: Z = 6.70, P < 0.00001). Pulsed radiofrequency combined with ozone is an effective treatment for zoster-associated pain that can effectively alleviate patients' pain and improve sleep quality, providing a new treatment option for zoster-associated pain in the future.
脉冲射频联合臭氧治疗是近年来带状疱疹相关疼痛的一种新治疗方法。探讨脉冲射频联合臭氧治疗带状疱疹相关疼痛的疗效。我们检索了常用的英文数据库(Cochrane Library、PubMed、CINAHL、Embase和Web of Science)和中文数据库(CNKI、万方、CBM和VIP数据库)进行随机对照试验。两位研究者在设定条件的基础上独立筛选文献,并从纳入的文献中提取数据。meta分析通过Review Manager 5.4软件进行。对18项研究进行meta分析,共纳入1496名参与者(实验组742人,对照组754人)。结果表明,脉冲射频联合臭氧治疗的单维疼痛评分较低(标准化平均差[SMD] = -1.55, 95%可信区间[CI] = [-2.04, -1.06];异质性:P < 0.00001, I2 = 94%;检验效果:Z = 6.18, P < 0.00001),疼痛评分指数较低(平均差异[MD] = -2.65, 95% CI = [-3.86, -1.44];异质性:P = 0.001, I2 = 85%;检验效果:Z = 4.29, P < 0.0001)和呈现疼痛强度评分(MD = -0.58, 95% CI = [-0.62, -0.54];异质性:P = 0.61, I2 = 0%;检验效应:Z = 27.91, P < 0.00001),较低的匹兹堡睡眠质量指数(MD = -1.62, 95% CI = [-2.94, -0.31];异质性:P < 0.00001, I2 = 93%;检验效果:Z = 2.42, P = 0.02),白细胞介素-6表达水平降低(SMD = -1.94, 95% CI = [-2.91, -0.97];异质性:P < 0.00001, I2 = 93%;检验效果:Z = 3.92, P < 0.0001),加巴喷丁用量降低(MD = -146.92, 95% CI = [-189.93, -103.91];异质性:P = 0.23, I2 = 30%;检验效果:Z = 6.70, P < 0.00001)。脉冲射频结合臭氧是带状疱疹相关疼痛的有效治疗方法,可有效减轻患者疼痛,改善睡眠质量,为今后带状疱疹相关疼痛的治疗提供新的选择。
{"title":"Effects of pulsed radiofrequency combined with ozone on zoster-associated pain: a systematic review and meta-analysis.","authors":"Xiao-Tong Ding, Jin-Zhao Huang, Qiu-Song Shen, Rui-Yu Wang, Hou-Ming Kan","doi":"10.4103/mgr.MEDGASRES-D-24-00150","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00150","url":null,"abstract":"<p><p>Pulsed radiofrequency combined with ozone therapy has been a newly proposed treatment method for zoster-associated pain in recent years. To explore the effectiveness of a regimen of pulsed radiofrequency combined with ozone for the treatment of zoster-associated pain. We searched commonly used English databases (the Cochrane Library, PubMed, CINAHL, Embase, and Web of Science) and Chinese databases (the CNKI, WanFang, CBM, and VIP databases) for randomized controlled trials. Two researchers independently screened the literature on the basis of the set conditions and extracted data from the included literature. The meta-analysis was conducted via Review Manager 5.4 software. A meta-analysis was conducted on 18 studies, with a total of 1496 participants (742 in the experimental group and 754 in the control group). The results revealed that the pulsed radiofrequency combined with ozone presented lower unidimensional pain scores (standardized mean difference [SMD] = -1.55, 95% confidence interval [CI] = [-2.04, -1.06]; heterogeneity: P < 0.00001, I2 = 94%; test effect: Z = 6.18, P < 0.00001), a lower pain rating index (mean difference [MD] = -2.65, 95% CI = [-3.86, -1.44]; heterogeneity: P = 0.001, I2 = 85%; test effect: Z = 4.29, P < 0.0001) and presented pain intensity scores (MD = -0.58, 95% CI = [-0.62, -0.54]; heterogeneity: P = 0.61, I2 = 0%; test effect: Z = 27.91, P < 0.00001), a lower Pittsburgh sleep quality index (MD = -1.62, 95% CI = [-2.94, -0.31]; heterogeneity: P < 0.00001, I2 = 93%; test effect: Z = 2.42, P = 0.02), and lower interleukin-6 expression levels (SMD = -1.94, 95% CI = [-2.91, -0.97]; heterogeneity: P < 0.00001, I2 = 93%; test effect: Z = 3.92, P < 0.0001), lower gabapentin consumption (MD = -146.92, 95% CI = [-189.93, -103.91]; heterogeneity: P = 0.23, I2 = 30%; test effect: Z = 6.70, P < 0.00001). Pulsed radiofrequency combined with ozone is an effective treatment for zoster-associated pain that can effectively alleviate patients' pain and improve sleep quality, providing a new treatment option for zoster-associated pain in the future.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"16 1","pages":"76-81"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}